ATAI Life Sciences Files 8-K with Financials
Ticker: ATAI · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1840904
| Field | Detail |
|---|---|
| Company | Atai Life Sciences N.V. (ATAI) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, reporting
TL;DR
ATAI Life Sciences filed an 8-K with financials, no major news.
AI Summary
On June 5, 2024, ATAI Life Sciences N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text. The company is incorporated in the Netherlands and has its principal executive offices in Berlin, Germany.
Why It Matters
This filing indicates that ATAI Life Sciences is fulfilling its reporting obligations by submitting financial statements and exhibits, which is standard procedure for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine submission of financial statements and exhibits, not indicating any new risks or significant events.
Key Players & Entities
- ATAI Life Sciences N.V. (company) — Registrant
- June 5, 2024 (date) — Date of report
- The Netherlands (jurisdiction) — State of incorporation
- Berlin, Germany (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits.
What is the exact name of the registrant?
The exact name of the registrant is ATAI Life Sciences N.V.
In which jurisdiction is ATAI Life Sciences N.V. incorporated?
ATAI Life Sciences N.V. is incorporated in The Netherlands.
Where are the principal executive offices of ATAI Life Sciences N.V. located?
The principal executive offices of ATAI Life Sciences N.V. are located in Berlin, Germany.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is June 5, 2024.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 9.4 · Accepted 2024-06-05 08:00:49
Filing Documents
- ef20030639_8k.htm (8-K) — 27KB
- ef20030639_ex99-1.htm (EX-99.1) — 86KB
- ef20030639_ex99-1slide1.jpg (GRAPHIC) — 211KB
- ef20030639_ex99-1slide2.jpg (GRAPHIC) — 555KB
- ef20030639_ex99-1slide3.jpg (GRAPHIC) — 308KB
- ef20030639_ex99-1slide4.jpg (GRAPHIC) — 282KB
- ef20030639_ex99-1slide5.jpg (GRAPHIC) — 240KB
- ef20030639_ex99-1slide6.jpg (GRAPHIC) — 147KB
- ef20030639_ex99-1slide7.jpg (GRAPHIC) — 209KB
- ef20030639_ex99-1slide8.jpg (GRAPHIC) — 290KB
- ef20030639_ex99-1slide9.jpg (GRAPHIC) — 153KB
- ef20030639_ex99-1slide10.jpg (GRAPHIC) — 332KB
- ef20030639_ex99-1slide11.jpg (GRAPHIC) — 312KB
- ef20030639_ex99-1slide12.jpg (GRAPHIC) — 252KB
- ef20030639_ex99-1slide13.jpg (GRAPHIC) — 285KB
- ef20030639_ex99-1slide14.jpg (GRAPHIC) — 298KB
- ef20030639_ex99-1slide15.jpg (GRAPHIC) — 149KB
- ef20030639_ex99-1slide16.jpg (GRAPHIC) — 355KB
- ef20030639_ex99-1slide17.jpg (GRAPHIC) — 356KB
- ef20030639_ex99-1slide18.jpg (GRAPHIC) — 306KB
- ef20030639_ex99-1slide19.jpg (GRAPHIC) — 160KB
- ef20030639_ex99-1slide20.jpg (GRAPHIC) — 308KB
- ef20030639_ex99-1slide21.jpg (GRAPHIC) — 241KB
- ef20030639_ex99-1slide22.jpg (GRAPHIC) — 302KB
- ef20030639_ex99-1slide23.jpg (GRAPHIC) — 131KB
- ef20030639_ex99-1slide24.jpg (GRAPHIC) — 208KB
- ef20030639_ex99-1slide25.jpg (GRAPHIC) — 252KB
- ef20030639_ex99-1slide26.jpg (GRAPHIC) — 167KB
- ef20030639_ex99-1slide27.jpg (GRAPHIC) — 422KB
- ef20030639_ex99-1slide28.jpg (GRAPHIC) — 339KB
- ef20030639_ex99-1slide29.jpg (GRAPHIC) — 291KB
- ef20030639_ex99-1slide30.jpg (GRAPHIC) — 142KB
- ef20030639_ex99-1slide31.jpg (GRAPHIC) — 354KB
- ef20030639_ex99-1slide32.jpg (GRAPHIC) — 363KB
- ef20030639_ex99-1slide33.jpg (GRAPHIC) — 376KB
- ef20030639_ex99-1slide34.jpg (GRAPHIC) — 182KB
- ef20030639_ex99-1slide35.jpg (GRAPHIC) — 133KB
- ef20030639_ex99-1slide36.jpg (GRAPHIC) — 315KB
- ef20030639_ex99-1slide37.jpg (GRAPHIC) — 695KB
- 0001140361-24-028944.txt ( ) — 14624KB
- atai-20240605.xsd (EX-101.SCH) — 4KB
- atai-20240605_lab.xml (EX-101.LAB) — 22KB
- atai-20240605_pre.xml (EX-101.PRE) — 16KB
- ef20030639_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On June 5, 2024, atai Life Sciences N.V. (the "Company") posted to the Company's corporate website at www.atai.life an investor presentation (the "Investor Presentation") to be used from time to time in meetings with investors and analysts. A copy of the Investor Presentation is attached as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated June 5, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATAI LIFE SCIENCES N.V. Date: June 5, 2024 By: /s/ Florian Brand Name: Florian Brand Title: Chief Executive Officer